• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Is Drawing Fresh Attention To LivaNova (LIVN)?

    Simply Wall St·10/25/2026 20:22:11
    語音播報

    What the CORE-VNS data means for LivaNova stock

    The new CORE-VNS results give LivaNova (LIVN) something concrete in hand. Investors now have peer reviewed, 36 month outcomes on its VNS Therapy in drug resistant epilepsy, rather than short term snapshots.

    The study followed 531 people across 61 sites in 16 countries, which is a relatively broad data set for a device trial. That scale matters because it helps reduce the risk that outcomes are driven by a narrow patient mix or a single clinical practice style.

    Results were not limited to seizure counts. Median seizure frequency fell 76% from baseline for participants with 36 month data, 64% reached at least a 50% reduction, and nearly half of that group saw cuts of 80% or more. In addition, 16% achieved complete seizure freedom and 28% had a full reduction in the seizure types they had at baseline.

    For a drug resistant population, even partial seizure control can be meaningful for daily life. In this cohort, 45% reported better quality of life by 36 months, while seizure related hospitalizations declined 73% and emergency visits also moved lower compared with baseline. That combination touches both patient experience and cost of care, two levers that often influence how payers and clinicians view a therapy.

    Retention is another piece investors tend to watch in long follow up work. Of more than 800 people in the broader CORE VNS program, 531 went into this analysis and 426 completed the full 36 months, an 80% retention rate. Investigators reported that benefits held up over time, with more participants moving into higher response categories and relatively few slipping back.

    Importantly for a commercial product, no new safety concerns were identified over the 3 year period. For a company like LivaNova, which already reports US$1.47b in annual revenue across cardiopulmonary and neuromodulation, that kind of long term safety and effectiveness profile can be relevant to how clinicians think about using its devices in a real world setting.

    LivaNova shares trade at US$80.90 after a small 1 day dip of 0.46%. However, the 7 day share price return of 4.28% and year to date gain of 33.41% suggest momentum has been building, backed by a 47.39% 1 year total shareholder return and 71.43% over three years.

    Scan beyond LivaNova and see how other potential compounders measure up on seizure care, balance-sheet strength, and pricing power with the hand-picked 34 healthcare AI stocks list.

    LivaNova now trades around US$80.90 after a strong year. The CORE VNS data is in, and the share price has already responded. Does the current valuation still skew the risk reward toward buyers?

    Most Popular Narrative: 9% Undervalued

    LivaNova closed at $80.90 while the most widely followed narrative pegs fair value at $89.10, implying a modest gap the CORE-VNS data now feeds into through longer term growth and margin assumptions. For anyone tracking the stock, that narrative rests heavily on how cardiopulmonary and neuromodulation can support steady cash generation rather than sharp inflection moves.

    The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

    See why 5 investors see LivaNova as 9% undervalued.

    Result: Fair Value of $89.10 (UNDERVALUED)

    Still, the bullish LivaNova story depends on reimbursement support and steady procedure volumes. Setbacks on either front could quickly undercut those fair value assumptions.

    Find out about the key risks to this LivaNova narrative.

    Next Steps

    Plenty of optimism runs through this story, yet the tension between upside and risk is still real, especially with fresh CORE VNS data in the mix. Act while the facts are front of mind, pressure test the bullish case against the concerns, and then decide where you stand by reviewing the 4 key rewards and 1 important warning sign.

    Ready for more LivaNova-sized opportunities?

    Do not stop with one idea. Use the Simply Wall St screener to surface fresh candidates that fit your style before the next wave of investors crowds in.